查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600592

細胞治療市場：按細胞類型、治療類型、應用和最終用戶分類 - 2025-2030 年全球預測

Cell Therapy Market by Cell Type (Differentiated Cell, Stem Cell), Therapy Type (Allogenic Therapies, Autologous Therapies), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

細胞治療市場2023年估值為86.6億美元，預計到2024年將達到96億美元，複合年成長率為10.93%，預計到2030年將達到179.1億美元。

細胞療法再生醫學的前沿是使用活細胞來修復或替換受損的組織和器官。此治療方法的應用範圍廣泛，包括腫瘤學、神經學、骨科、心血管疾病等。需求在於它有可能為傳統治療方法不足的慢性疾病、遺傳性疾病和退化性疾病提供解決方案。最終用途部分包括對這些治療方法的開發、測試和應用至關重要的臨床研究機構、醫院和專科中心。市場成長要素包括慢性病盛行率的增加、細胞研究的進步以及有利的法律規範。最新的機會在於不斷發展的領域，例如個人化醫療（其中 CAR-T 細胞療法在特定癌症中處於主導）以及幹細胞療法的擴大應用。採用人工智慧和機器學習來改善細胞發育過程也是一個充滿希望的前景。然而，複雜的監管環境、高生產成本以及嚴格政策導致的商業化有限等挑戰正在限制成長潛力。由於道德問題和有限的長期療效資料，市場接受度也存在猶豫。創新應著重於可擴展的製造解決方案、降低成本和先進的臨床測試，以確保安全性和有效性。公司還可以探索與學術機構建立合作夥伴關係，以實現研究協同效應。市場是動態的，其特點是技術快速發展，公司必須保持靈活性並遵守不斷變化的法規。醫療基礎設施和生物技術投資不斷增加的新興市場存在成長機會。此外，投資教育宣傳活動以提高公眾意識和理解可以提高市場接受度。為了取得成功，相關人員必須利用技術創新和協作創新來克服挑戰並推動細胞療法在全球的採用和成功。

主要市場統計
基準年[2023] 86.6億美元
預測年份 [2024] 96億美元
預測年份 [2030] 179.1億美元
複合年成長率（%） 10.93%

市場動態：揭示快速發展的細胞治療市場的關鍵市場洞察

供需的動態交互作用正在改變細胞治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 政府增加對生物技術創新和細胞療法核准率的投資
    • 改善細胞治療供應鏈
  • 市場限制因素
    • 與幹細胞移植相關的副作用
  • 市場機會
    • 嵌合體抗原受體 T 細胞 (CAR-T) 療法以及 ESC（胚胎幹細胞）和 iPSC（誘導性多功能幹細胞）在癌症治療中的應用取得進展
    • 增加幹細胞在治療神經系統疾病的應用
  • 市場問題
    • 與幹細胞使用相關的倫理和藥理學問題

波特五力：駕馭細胞治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解細胞治療市場的外部影響

外部宏觀環境因素在塑造細胞治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解細胞治療市場的競爭格局

對細胞治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：細胞治療市場供應商的績效評估

FPNV定位矩陣是評估細胞治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 政府增加對生物技術創新的投資和細胞療法的核准率
      • 改善細胞治療供應鏈
    • 抑制因素
      • 與幹細胞移植相關的副作用
    • 機會
      • 嵌合體抗原受體 T 細胞 (CAR-T) 療法以及 ESC（胚胎幹細胞）和 iPSC（誘導性多功能幹細胞）在癌症治療中的應用取得進展
      • 增加幹細胞在治療神經系統疾病的應用
    • 任務
      • 與使用幹細胞相關的倫理和藥理學問題
  • 市場區隔分析
    • 細胞類型：幹細胞治療用途的進展
    • 治療類型：在個人化醫療中擴大採用自體細胞療法
    • 應用：細胞療法在皮膚科應用的進展
    • 最終使用者：細胞療法在醫院和診所疾病管理的多種應用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境
  • 客戶客製化

第6章細胞治療市場：依細胞類型

  • 介紹
  • 分化細胞
  • 幹細胞

第7章細胞治療市場：依治療類型

  • 介紹
  • 同種異體療法
  • 家庭治療

第8章細胞治療市場：依應用分類

  • 介紹
  • 自體免疫疾病
  • 皮膚科
  • 肌肉骨骼治療
  • 腫瘤學

第9章細胞治療市場：依最終使用者分類

  • 介紹
  • 生物技術和製藥公司
  • 醫院和診所
  • 研究所

第10章美洲細胞治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太細胞治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲細胞治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Pluri推出新的細胞療法 CDMO 部門
    • Max Healthcare 推出 CAR-T 細胞療法，以改善新德里的癌症治療
    • 拜耳開設第一家細胞療法製造工廠，推動全球再生醫學發展

公司名單

  • Athersys, Inc.
  • Sartorius AG
  • BioNTech SE
  • Anterogen Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Novartis AG
  • Thermo Fisher Scientific, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Vericel Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Mesoblast Ltd.
  • Castle Creek Biosciences, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • Stemedica Cell Technologies, Inc.
  • Medipost Co., Ltd.
  • Smith & Nephew PLC
  • Bone Therapeutics SA
  • NuVasive, Inc.
  • Kolon TissueGene, Inc.
  • Lonza Group Ltd.
  • Astellas Pharma Inc.
  • TegoScience
  • Bristol-Myers Squibb Company
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market was valued at USD 8.66 billion in 2023, expected to reach USD 9.60 billion in 2024, and is projected to grow at a CAGR of 10.93%, to USD 17.91 billion by 2030.

Cell therapy, a cutting-edge frontier in regenerative medicine, involves the administration of living cells to repair or replace damaged tissues and organs. The scope of this therapy spans applications in oncology, neurology, orthopedics, and cardiovascular conditions among others. Its necessity is driven by its potential to provide solutions for chronic diseases, genetic disorders, and degenerative conditions where traditional treatments fall short. End-use sectors include clinical research organizations, hospitals, and specialized cell therapy centers, all crucial for developing, testing, and applying these therapies. Market growth factors include increasing prevalence of chronic diseases, advancements in cell-based research, and favorable regulatory frameworks. The latest opportunities lie in evolving areas like personalized medicine, with CAR-T cell therapy leading the charge against specific cancers, and expanding applications in stem cell therapy. Adoption of AI and machine learning in improving cell development processes is another promising prospect. However, challenges such as complex regulatory landscapes, high production costs, and limited commercialization due to stringent policies restrain growth potential. There is also hesitancy in market acceptance stemming from ethical concerns and limited long-term efficacy data. Innovations should focus on scalable manufacturing solutions, reducing costs, and ensuring safety and efficacy through advanced clinical trials. Companies could explore partnerships with academic institutions for research synergies. The market is dynamic, marked by rapid technological evolution, necessitating players to remain agile and compliant with changing regulations. Opportunities for growth are present in developing markets where healthcare infrastructure advancements and investments in biotech are on the rise. Additionally, investing in educational campaigns to improve public perception and understanding could boost market acceptance. To succeed, stakeholders must navigate the challenges while leveraging technological and collaborative innovations to drive the adoption and success of cell therapies worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 8.66 billion
Estimated Year [2024] USD 9.60 billion
Forecast Year [2030] USD 17.91 billion
CAGR (%) 10.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell Therapy Market

The Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
    • Improvements in Cell Therapy Supply Chain
  • Market Restraints
    • Side Effects Related to the Stem Cell Transplant
  • Market Opportunities
    • Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
    • Increasing Use of Stem Cells for the Treatment of Neurological disorders
  • Market Challenges
    • Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues

Porter's Five Forces: A Strategic Tool for Navigating the Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell Therapy Market

A detailed market share analysis in the Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Athersys, Inc., Sartorius AG, BioNTech SE, Anterogen Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, Thermo Fisher Scientific, Inc., Stempeutics Research Pvt. Ltd., Vericel Corporation, JCR Pharmaceuticals Co., Ltd., Mesoblast Ltd., Castle Creek Biosciences, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Stemedica Cell Technologies, Inc., Medipost Co., Ltd., Smith & Nephew PLC, Bone Therapeutics SA, NuVasive, Inc., Kolon TissueGene, Inc., Lonza Group Ltd., Astellas Pharma Inc., TegoScience, and Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cell Type, market is studied across Differentiated Cell and Stem Cell.
  • Based on Therapy Type, market is studied across Allogenic Therapies and Autologous Therapies.
  • Based on Application, market is studied across Autoimmune Diseases, Dermatology, Musculoskeletal Therapies, and Oncology.
  • Based on End-User, market is studied across Biotechnology and Pharmaceutical Companies, Hospitals and Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
      • 5.1.1.2. Improvements in Cell Therapy Supply Chain
    • 5.1.2. Restraints
      • 5.1.2.1. Side Effects Related to the Stem Cell Transplant
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
      • 5.1.3.2. Increasing Use of Stem Cells for the Treatment of Neurological disorders
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cell Type: Advancements in stem cells for therapeutic applications
    • 5.2.2. Therapy Type: Increasing adoption of autologous cell therapies for personalized medicines
    • 5.2.3. Application: Advancements in dermatological applications of cell therapies
    • 5.2.4. End-User: Diverse applications of cell therapies in hospitals and clinics for disease management
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Cell Therapy Market, by Cell Type

  • 6.1. Introduction
  • 6.2. Differentiated Cell
  • 6.3. Stem Cell

7. Cell Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Allogenic Therapies
  • 7.3. Autologous Therapies

8. Cell Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Dermatology
  • 8.4. Musculoskeletal Therapies
  • 8.5. Oncology

9. Cell Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Biotechnology and Pharmaceutical Companies
  • 9.3. Hospitals and Clinics
  • 9.4. Research Institutes

10. Americas Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Pluri Launches New Cell Therapy CDMO Division
    • 13.3.2. Max Healthcare Launches CAR-T Cell Therapy to Improve Cancer Care in Delhi-NCR
    • 13.3.3. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale

Companies Mentioned

  • 1. Athersys, Inc.
  • 2. Sartorius AG
  • 3. BioNTech SE
  • 4. Anterogen Co., Ltd.
  • 5. Takeda Pharmaceutical Company Limited
  • 6. Pfizer Inc.
  • 7. Novartis AG
  • 8. Thermo Fisher Scientific, Inc.
  • 9. Stempeutics Research Pvt. Ltd.
  • 10. Vericel Corporation
  • 11. JCR Pharmaceuticals Co., Ltd.
  • 12. Mesoblast Ltd.
  • 13. Castle Creek Biosciences, Inc.
  • 14. FUJIFILM Holdings Corporation
  • 15. Gilead Sciences, Inc.
  • 16. Stemedica Cell Technologies, Inc.
  • 17. Medipost Co., Ltd.
  • 18. Smith & Nephew PLC
  • 19. Bone Therapeutics SA
  • 20. NuVasive, Inc.
  • 21. Kolon TissueGene, Inc.
  • 22. Lonza Group Ltd.
  • 23. Astellas Pharma Inc.
  • 24. TegoScience
  • 25. Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY DIFFERENTIATED CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023